The Goodwin Life Sciences and Private Equity team advised Hillhouse Capital on its investment in Everest Medicines as a co-lead investor in Everest Medicine’s Series C financing of $310 million. The transaction reflects a growing convergence among the private equity, life sciences and technology industries, a market intersection in which Goodwin is uniquely specialized.
Hillhouse Capital is a long-term investor focused on partnering with world-class entrepreneurs to help them grow their businesses globally. Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia.
Proceeds from the financing will be used to advance clinical development of Everest Medicines’ robust pipeline of novel therapeutic candidates and build out a strong commercial infrastructure to support the next phase of growth.